Scientific scope and capacities.
The vaccines and immunotherapy pillar combines antigen/assay development, infection biology and host-response stratification. Capabilities include recombinant technologies, advanced respiratory infection models (including ALI epithelial models), functional assays and specialised animal models supporting mechanistic studies and preclinical vaccine evaluation. The platform is aligned with national and European preparedness priorities and applies personalised-medicine principles by addressing variability in immune responses (responders vs. non-responders).
Main services to users (examples).
- Antigen design and recombinant production workflows;
- Infection and immunity models for mechanistic studies and candidate evaluation;
- Immunoprofiling and biomarker discovery supporting precision vaccination and immunotherapy strategies;
- Preparedness-oriented translational support, demonstrated and strengthened during the COVID-19 period through rapid mobilisation of diagnostics, sequencing, data workflows and validation activities across the network.
The EATRIS Vaccines platform covers the entire vaccine development and production pipeline ranging from late-phase pre-clinical development to clinical trials. Partnering with most advanced development centers, the Vaccines platform offers proven state-of-the-art resources for all critical issues related to vaccine development. They include specialized GMP provision with accompanying formulation and adjuvantation; disease specific animal models with facilities up to BSL3 containment; immunomonitoring, and access to clinical facilities with relevant patient groups up to phase IIa trials. The EATRIS Vaccines platform also provides a network of experts on regulatory affairs specialized in vaccines, to ensure compliance with all pre-clinical and clinical development guidelines within Europe. This allows us to bring projects forward in the minimum of time and with the most efficient use of resources, while ensuring high levels of scientific discipline and regulatory compliance.
EATRIS-CZ participation
- IM
Major technologies/infrastructures
- flow cytometry, BSL2/3 labs, animal facilities, imaging, specialized cell culture and modification techniques